Get started
Author

Colin Liang

ORCID: 0000-0002-1507-071X
Observed ORCID: 0000-0002-1507-071X
OpenAlex ID: A5015741023
Discovery of TNG462: A Highly Potent and Selective MTA-Cooperative PRMT5 Inhibitor to Target Cancers with MTAP Deletion
2025 · Kevin M. Cottrell, Kimberly J. Briggs, et al. · Journal of Medicinal Chemistry · 45
444 TNG260, a CoREST-selective deacetylase inhibitor, reverses anti-PD1 resistance driven by loss of STK11
2022 · Leanne Ahronian, Xinyuan Wu, et al. · Journal for ImmunoTherapy of Cancer · 8
PDF
Abstract 4968: Characterization of the clinical development candidate TNG348 as a potent and selective inhibitor of USP1 for the treatment of BRCA1/2mut cancers
2023 · Antoine Simoneau, Hsin-Jung Wu, et al. · Cancer Research · 6
Abstract ND12: TNG260: A novel, orally active, CoREST-selective deacetylase inhibitor for the treatment of STK11-mutant cancers
2023 · Leanne G. Ahronian, Minjie Zhang, et al. · Cancer Research · 5
TNG961 Is a Selective Oral HBS1L Molecular Glue Degrader for the Treatment of FOCAD- Deleted Cancers
2026 · Hilary E. Nicholson, Douglas A. Whittington, et al. · Cancer Discovery · 3
The Discovery of TNG456: A Highly Potent, Selective, Brain-Penetrant MTA-Cooperative PRMT5 Inhibitor for the Treatment of MTAP -Deleted Cancers
2026 · Kevin M. Cottrell, Kimberly J. Briggs, et al. · Journal of Medicinal Chemistry · 2
PDF
Abstract B027: TNG961: A selective oral molecular glue degrader of HBS1L inducing tumor regression in naïve and PRMT5i-refractory FOCAD-deleted models
2025 · Katherine Lazarides, Minjie Zhang, et al. · Molecular Cancer Therapeutics · 1
792 TNG917: a potent and orally active inhibitor of euchromatic histone lysine methyltransferases (EHMT1/2) for the treatment of immune-cold tumors
2024 · Alvin Lu, Brian Haines, et al. · Journal for ImmunoTherapy of Cancer · 1
Abstract ND03: TNG961: A selective oral molecular glue degrader of HBS1L for the treatment of FOCAD-deficient cancers
2026 · Douglas A. Whittington, Frank J. Bruzzese, et al. · Cancer Research
Abstract 3242: TNG917 is a clinical-grade, potent and selective inhibitor of EHMT1/2 for the treatment of immune cold tumors
2024 · Alvin Lu, Brian Haines, et al. · Cancer Research
Works count: 10
Citation count: 71
H-index: 4
I10-index: 1
Year
Topic
Type